Reaction: Tazemetostat to 1 product
- Reaction
- Reaction type
- Not Available
- Direction
- Major circulating metabolite?
- No
- Spontaneous?
- No
- Activity
- inactive
- References
- Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V: Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9. [Article]
- FDA Approved Drug Products: Tazverik (tazemetostat) tablets for oral use [Link]
- Comments
- Not Available
- Enzymes
Enzyme Km Vmax Role Cytochrome P450 3A4 Not Available Not Available confirmed